Fortress Biotech stock: Subsidiary licenses FB-607 from Cedars-Sinai

Published on 11/12/2026 at 03:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fortress Biotech stock drew attention after a subsidiary licensed FB-607 from Cedars-Sinai for irritable bowel syndrome with diarrhea. The Phase 2 study is ongoing.

Fortress advances FB-607 program

A majority-owned Fortress subsidiary secured exclusive rights from Cedars-Sinai to develop FB-607 for IBS-D.
The candidate combines rifaximin and N-acetylcysteine in an enteric-coated formulation.
A randomized, double-blind Phase 2 study is evaluating two doses against placebo.

FBIO, US34960Q3074, Illustration mit AI erstellt.

Fortress Biotech announced on Tuesday, November 10, 2026, that a majority-owned and controlled subsidiary had entered an exclusive licensing agreement with Cedars-Sinai to develop FB-607 for irritable bowel syndrome with diarrhea, or IBS-D. The company described the transaction in its investor-relations news flow and outlined the development program in the release.

FB-607 is an enteric-coated, pH-sensitive combination of rifaximin and N-acetylcysteine. The formulation is designed to improve rifaximin access to bacteria in the intestinal mucus layer and may also support development in other indications, including hepatic encephalopathy, according to StockTitan.

Phase 2 study sets next milestone

The ongoing multi-center trial is randomized, double-blind and placebo-controlled. It compares two FB-607 dose levels with placebo, uses 14 days of treatment and follows participants through week 14. The study is assessing safety, efficacy and pharmacokinetics, with endpoints covering abdominal pain, stool consistency, stool frequency and overall response.

The company cited earlier proof-of-concept findings for the rifaximin and N-acetylcysteine combination across stool consistency, stool frequency, abdominal pain, bloating and breath testing. Those findings are preliminary and do not establish the outcome of the current Phase 2 trial.

Fortress builds a diversified portfolio

Fortress Biotech is a United States biopharmaceutical company focused on acquiring and advancing prescription products and drug candidates. Its portfolio spans oncology, dermatology and rare diseases and includes marketed products as well as preclinical and clinical-stage programs, according to the company's investor-relations page. Fortress also holds interests in majority-owned and controlled partners, subsidiaries and selected minority investments. This portfolio model gives the company exposure to several therapeutic areas rather than a single product line.